

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 23, 2015**

---

**SYNTA PHARMACEUTICALS CORP.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-33277**  
(Commission File Number)

**04-3508648**  
(IRS Employer  
Identification No.)

**45 Hartwell Avenue**  
**Lexington, MA 02421**  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(781) 274-8200**

---

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) On April 22, 2015, Anne Whitaker notified the Board of Directors of Synta Pharmaceutical Corp. (“Synta”) that she was resigning as Synta’s President and Chief Executive Officer and as a member of Synta’s Board of Directors, effective as of May 7, 2015.

(c) (d) In connection with Ms. Whitaker’s resignation, on April 23, 2015, the Board of Directors (i) appointed Chen Schor, Synta’s current Executive Vice President and Chief Operating Officer, as President and Chief Executive Officer, to be effective as of May 7, 2015 and (ii) appointed Mr. Schor as a Class I director with a term expiring at the annual meeting of stockholders to be held in 2017, to be effective as of May 7, 2015, to fill the vacancy to be created by Anne Whitaker’s resignation. Information regarding Mr. Schor’s business experience and current employment arrangements with Synta is included in Synta’s Current Report on Form 8-K (File No. 001-33277) filed with the Securities and Exchange Commission on December 4, 2014, and is incorporated herein by reference.

There are no family relationships between Mr. Schor and any director or executive officer of Synta that are required to be disclosed pursuant to Item 401(d) of Regulation S-K. There are no related party transactions involving Synta that are required to be disclosed pursuant to Item 404(a) of Regulation S-K related to Mr. Schor.

On April 27, 2015, Synta Pharmaceuticals Corp. issued a press release announcing the foregoing management changes. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**ITEM 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit Number</b>	<b>Description</b>
10.1	Letter Agreement, dated December 3, 2014, between Synta Pharmaceuticals Corp. and Chen Schor (incorporated by reference to Exhibit 10.1 to in Synta’s Current Report on Form 8-K (File No. 001-33277) filed with the Securities and Exchange Commission on December 4, 2014)
10.2	Severance and Change of Control Agreement, dated December 3, 2014, between Synta Pharmaceuticals Corp. and Chen Schor (incorporated by reference to Exhibit 10.2 to in Synta’s Current Report on Form 8-K (File No. 001-33277) filed with the Securities and Exchange Commission on December 4, 2014)
99.1	Press Release, dated April 27, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SYNTA PHARMACEUTICALS CORP.**

Dated: April 27, 2015

/s/ Marc Schneebaum  
Marc Schneebaum  
Senior Vice President and Chief Financial Officer



Synta Pharmaceuticals Corp.  
45 Hartwell Avenue  
Lexington, MA 02421

tel: 781 541 7213  
fax: 781 274 1270

[www.syntapharma.com](http://www.syntapharma.com)

### **Synta Announces Chen Schor Named President, Chief Executive Officer and Director**

**LEXINGTON, Mass. — April 27, 2015** — Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that Chen Schor, Executive Vice President, Chief Operating Officer, has been named President, Chief Executive Officer and a Director of the Company, effective May 7, 2015. Mr. Schor replaces Anne Whitaker, who is stepping down from her roles at Synta to pursue a professional opportunity at a large multinational pharmaceutical company.

“We appreciate Anne’s contributions to Synta during her tenure here, including her work in streamlining the organization and prioritizing its rich pipeline opportunities,” said Keith Gollust, Chairman of Synta. “We understand her rationale for leaving Synta was due to both personal and professional goals. This new leadership opportunity allows her to be located closer to her family. We wish her the best in her future endeavors.”

Mr. Gollust added: “Thanks to a deep management team at Synta, the Company remains well positioned to continue executing our broad ganetespib development program, including the GALAXY-2 Phase 3 study in non-small cell lung adenocarcinoma, and advancing our HDC pipeline toward the clinic. Chen has been an integral part of this team for several months, and the Board is confident that his background and expertise are ideally suited for guiding the Company through this exciting period.”

“With multiple large, randomized investigator- and company-sponsored ganetespib studies ongoing, a promising profile emerging from our lead HDC pipeline assets and the capital to reach several important milestones, Synta holds the potential to realize significant value for our shareholders in the near-term,” said Mr. Schor. “I look forward to working with the Board and our talented management team to help realize this value.”

Mr. Schor joined Synta as Executive Vice President and Chief Operating Officer in December 2014. Mr. Schor has over 15 years of leadership experience in biotechnology, medical devices, business development and private equity. Mr. Schor served as Vice President, Global Branded Products Business Development and Pipeline Management at Teva Pharmaceuticals and in leadership positions at several emerging private and public companies. During his career, Mr. Schor has led licensing and M&A transactions valued at over \$8 billion with partners that include GSK, Amgen, Pfizer, Merck KGaA and OncoGeneX, among others. Mr. Schor was a Partner at Yozma Venture Capital, where he led the foundation and growth of multiple therapeutic companies from inception to significant commercial success and exit. Mr. Schor holds a Master in Business Administration, a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).

#### **About Synta Pharmaceuticals**

Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Synta’s lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in

---

several clinical trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell lung cancer. Building on its extensive expertise in the science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor Drug Conjugate (HDC) small molecule drug development program. IND enabling studies have commenced for the first clinical candidate from the HDC program, STA-12-8666, and preclinical evaluation of additional HDC candidates is ongoing. For more information, please visit [www.syntapharma.com](http://www.syntapharma.com).

**Safe Harbor Statement**

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the use of forward-looking terminology such as “will”, “would”, “should”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “may”, “estimates”, “predicts”, “projects”, or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to Synta’s potential to realize significant value for our shareholders in the near-term, reflect Synta’s current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in “Risk Factors” of our Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

###

**Contacts:**

**Investors:**

Synta Pharmaceuticals Corp.  
Daniel Cole  
781-541-7250  
[dcole@syntapharma.com](mailto:dcole@syntapharma.com)

Argot Partners  
Andrea Rabney  
(212) 600-1494  
[andrea@argotpartners.com](mailto:andrea@argotpartners.com)

**Media:**

Argot Partners  
Eliza Schleifstein  
(917) 763-8106  
[eliza@argotpartners.com](mailto:eliza@argotpartners.com)

---